Management of fungal lung disease in the immunocompromised

Therapeutic Advances in Respiratory Disease

Volumn 5, Issue 5, 2011, Pages 305-324

  Islam, Anowara ^a   Mody, Christopher H ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

antifungal treatment; aspergillosis; cryptococcosis; fungal lung disease; histoplasmosis; immunocompromised hosts

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ATOVAQUONE; CARBAMAZEPINE; CASPOFUNGIN; CLINDAMYCIN; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; METHYLPREDNISOLONE; MICAFUNGIN; MONOCLONAL ANTIBODY; PENTAMIDINE; POSACONAZOLE; PREDNISONE; PRIMAQUINE; RIFABUTIN; RIFAMPICIN; SULFAMETHOXAZOLE; TACROLIMUS; TRIMETHOPRIM; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIBIOTIC PROPHYLAXIS; ASPERGILLUS; BLASTOMYCES DERMATITIDIS; BLASTOMYCOSIS; CENTRAL NERVOUS SYSTEM BLASTOMYCOSIS; CENTRAL NERVOUS SYSTEM CRYPTOCOCCOSIS; CENTRAL NERVOUS SYSTEM INFECTION; CHRONIC NECROTIZING LUNG ASPERGILLOSIS; COCCIDIOIDES; COCCIDIOIDOMYCOSIS; CRITICALLY ILL PATIENT; CRYPTOCOCCAL MENINGOENCEPHALITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DISEASE SEVERITY; DISSEMINATED BLASTOMYCOSIS; DISSEMINATED CRYPTOCOCCOSIS; DRUG MEGADOSE; FUNGUS IDENTIFICATION; HIGH RISK PATIENT; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOXEMIA; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION RISK; INVASIVE ASPERGILLOSIS; INVASIVE LUNG ASPERGILLOSIS; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG ASPERGILLOSIS; LUNG BLASTOMYCOSIS; LUNG COCCIDIOIDOMYCOSIS; LUNG HISTOPLASMOSIS; LUNG MYCOSIS; LUNG ZYGOMYCOSIS; MENINGOENCEPHALITIS; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PULMONARY CRYPTOCOCCOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RESPIRATORY DISTRESS; REVIEW; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; ZYGOMYCETES; ZYGOMYCOSIS;

ANIMALS; ANTIFUNGAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; LUNG DISEASES, FUNGAL; PREVALENCE; SEVERITY OF ILLNESS INDEX;

EID: 80052640978     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465811398720     Document Type: Review

References (93)

1. Ashley E.S.D. Lewis R. Lewis J.S. Martin C. Andes D. (2006) Pharmacology of systemic antifungal agents. Clin Infect Dis 43: S28's39.
2. Assi M.A. Sandid M.S. Baddour L.M. Roberts G.D. Walker R.C. (2007) Systemic histoplasmosis: a 15-year retrospective institutional review of 111 patients. Medicine (Baltimore) 86: 162–169.
3. Bennett J.E. Dismukes W.E. Duma R.J. Medoff G. Sande M.A. Gallis H. (1979) A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 301: 126–131.
4. Binder R.E. Faling L.J. Pugatch R.D. Mahasaen C. Snider G.L. (1982) Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltimore) 61: 109–124.
5. Blankenship J.R. Singh N. Alexander B.D. Heitman J. (2005) Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens. J Clin Microbiol 43: 464–467.
6. Bozzette S.A. Larsen R.A. Chiu J. Leal M.A. Jacobsen J. Rothman P. (1991) A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 324: 580–584.
7. Brouwer A.E. Rajanuwong A. Chierakul W. Griffin G.E. Larsen R.A. White N.J. (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363: 1764–1767.
8. Cameron M.L. Bartlett J.A. Gallis H.A. Waskin H.A. (1991) Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis 13: 64–67.
9. Chamilos G. Luna M. Lewis R.E. Bodey G.P. Chemaly R. Tarrand J.J. (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 91: 986–989.
10. Chapman S.W. Dismukes W.E. Proia L.A. Bradsher R.W. Pappas P.G. Threlkeld M.G. (2008) Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 46: 1801–1812.
11. Clark B. Foster R. Tunbridge A. Green S. (2005) A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole. J Infect 51: e177–e180.
12. Clark T.A. Hajjeh R.A. (2002) Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 15: 569–574.
13. Cornely O.A. Maertens J. Winston D.J. Perfect J. Ullmann A.J. Walsh T.J. (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356: 348–359.
14. Crampton T.L. Light R.B. Berg G.M. Meyers M.P. Schroeder G.C. Hershfield E.S. (2002) Epidemiology and clinical spectrum of blastomycosis diagnosed at Manitoba hospitals. Clin Infect Dis 34: 1310–1316.
15. Cuellar-Rodriguez J. Avery R.K. Lard M. Budev M. Gordon S.M. Shrestha N.K. (2009) Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin Infect Dis 49: 710–716.
16. Denning D.W. (1998) Invasive aspergillosis. Clin Infect Dis 26: 781–803. quiz 804–785.
17. Denning D.W. (2003) Echinocandin antifungal drugs. Lancet 362: 1142–1151.
18. Dismukes W.E. Bradsher R.W. Jr Cloud G.C. Kauffman C.A. Chapman S.W. George R.B. (1992) Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med 93: 489–497.
19. Dismukes W.E. Cloud G. Gallis H.A. Kerkering T.M. Medoff G. Craven P.C. (1987) Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 317: 334–341.
20. Dromer F. Mathoulin S. Dupont B. Brugiere O. Letenneur L. (1996) Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. Clin Infect Dis 22(Suppl. 2): S154's160.
21. Dworkin M.S. Duckro A.N. Proia L. Semel J.D. Huhn G. (2005) The epidemiology of blastomycosis in Illinois and factors associated with death. Clin Infect Dis 41: e107–e111.
22. Fukuda T. Boeckh M. Carter R.A. Sandmaier B.M. Maris M.B. Maloney D.G. (2003) Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 102: 827–833.
23. Furcolow M.L. (1963) The Use of Amphotericin B in Blastomycosis, Cryptococcosis and Histoplasmosis. Med Clin North Am 47: 1119–1130.
24. Galgiani J.N. Ampel N.M. Blair J.E. Catanzaro A. Johnson R.H. Stevens D.A. (2005) Coccidioidomycosis. Clin Infect Dis 41: 1217–1223.
25. Gascon J. Torres J.M. Jimenez M. Mejias T. Trivino L. Gobbi F. (2005) Histoplasmosis infection in Spanish travelers to Latin America. Eur J Clin Microbiol Infect Dis 24: 839–841.
26. Gauthier G.M. Safdar N. Klein B.S. Andes D.R. (2007) Blastomycosis in solid organ transplant recipients. Transpl Infect Dis 9: 310–317.
27. Goldman M. Zackin R. Fichtenbaum C.J. Skiest D.J. Koletar S.L. Hafner R. (2004) Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis 38: 1485–1489.
28. Groll A.H. Shah P.M. Mentzel C. Schneider M. Just-Nuebling G. Huebner K. (1996) Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 33: 23–32.
29. Herbrecht R. Denning D.W. Patterson T.F. Bennett J.E. Greene R.E. Oestmann J.W. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347: 408–415.
30. Johnson L.B. Kauffman C.A. (2003) Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36: 630–637.
31. Johnson P.C. Wheat L.J. Cloud G.A. Goldman M. Lancaster D. Bamberger D.M. (2002) Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 137: 105–109.
32. Johnston S.R. Corbett E.L. Foster O. Ash S. Cohen J. (1992) Raised intracranial pressure and visual complications in AIDS patients with cryptococcal meningitis. J Infect 24: 185–189.
33. Jongwutiwes U. Sungkanuparph S. Kiertiburanakul S. (2008) Comparison of clinical features and survival between cryptococcosis in human immunodeficiency virus (HIV)-positive and HIV-negative patients. Jpn J Infect Dis 61: 111–115.
34. Kauffman C.A. (2008) Diagnosis of histoplasmosis in immunosuppressed patients. Curr Opin Infect Dis 21: 421–425.
35. Kauffman C.A. (2009) Histoplasmosis. Clin Chest Med 30: 217–225, v.
36. Khayyata S. Soubani A.O. Bonnett M. Nassar H. Abidi M.H. Al-Abbadi M.A. (2007) The major autopsy findings in adult patients after hematopoietic stem cell transplantation. Ann Transplant 12: 11–18.
37. King M.D. Perlino C.A. Cinnamon J. Jernigan J.A. (2002) Paradoxical recurrent meningitis following therapy of cryptococcal meningitis: an immune reconstitution syndrome after initiation of highly active antiretroviral therapy. Int J STD AIDS 13: 724–726.
38. Laniado-Laborin R. (2007) Expanding understanding of epidemiology of coccidioidomycosis in the Western hemisphere. Ann N Y Acad Sci 1111: 19–34.
39. Lemos L.B. Baliga M. Guo M. (2001) Acute respiratory distress syndrome and blastomycosis: presentation of nine cases and review of the literature. Ann Diagn Pathol 5: 1–9.
40. Loulergue P. Bastides F. Baudouin V. Chandenier J. Mariani-Kurkdjian P. Dupont B. (2007) Literature review and case histories of Histoplasma capsulatum var. duboisii infections in HIV-infected patients. Emerg Infect Dis 13: 1647–1652.
41. Masri K. Mahon N. Rosario A. Mirza I. Keys T.F. Ratliff N.B. (2003) Reactive hemophagocytic syndrome associated with disseminated histoplasmosis in a heart transplant recipient. J Heart Lung Transplant 22: 487–491.
42. McKinnell J.A. Pappas P.G. (2009) Blastomycosis: new insights into diagnosis, prevention, and treatment. Clin Chest Med 30: 227–239, v.
43. McKinsey D.S. Spiegel R.A. Hutwagner L. Stanford J. Driks M.R. Brewer J. (1997) Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: incidence, risk factors, and pathophysiology. Clin Infect Dis 24: 1195–1203.
44. McKinsey D.S. Wheat L.J. Cloud G.A. Pierce M. Black J.R. Bamberger D.M. (1999) Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 28: 1049–1056.
45. Meyohas M.C. Roux P. Bollens D. Chouaid C. Rozenbaum W. Meynard J.L. (1995) Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS. Clin Infect Dis 21: 628–633.
46. Mody C.H. Toews G.B. Lipscomb M.F. (1988) Cyclosporin A inhibits the growth of Cryptococcus neoformans in a murine model. Infect Immun 56: 7–12.
47. Mody C.H. Toews G.B. Lipscomb M.F. (1989) Treatment of murine cryptococcosis with cyclosporin-A in normal and athymic mice. Am Rev Respir Dis 139: 8–13.
48. Morgan J. Wannemuehler K.A. Marr K.A. Hadley S. Kontoyiannis D.P. Walsh T.J. (2005) Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 43(Suppl. 1): S49's58.
49. Oren I. Haddad N. Finkelstein R. Rowe J.M. (2001) Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 66: 257–262.
50. Pappas P.G. Perfect J.R. Cloud G.A. Larsen R.A. Pankey G.A. Lancaster D.J. (2001) Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 33: 690–699.
51. Pappas P.G. Pottage J.C. Powderly W.G. Fraser V.J. Stratton C.W. McKenzie S. (1992) Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med 116: 847–853.
52. Pappas P.G. Threlkeld M.G. Bedsole G.D. Cleveland K.O. Gelfand M.S. Dismukes W.E. (1993) Blastomycosis in immunocompromised patients. Medicine (Baltimore) 72: 311–325.
53. Parish J.M. Blair J.E. (2008) Coccidioidomycosis. Mayo Clin Proc 83: 343–348. quiz 348–349.
54. Pascual A. Calandra T. Bolay S. Buclin T. Bille J. Marchetti O. (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46: 201–211.
55. Patterson J.E. (1999) Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis 1: 229–236.
56. Powderly W.G. Saag M.S. Cloud G.A. Robinson P. Meyer R.D. Jacobson J.M. (1992) A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 326: 793–798.
57. Recht L.D. Davies S.F. Eckman M.R. Sarosi G.A. (1982) Blastomycosis in immunosuppressed patients. Am Rev Respir Dis 125: 359–362.
58. Restrepo A. Tobon A. Clark B. Graham D.R. Corcoran G. Bradsher R.W. (2007) Salvage treatment of histoplasmosis with posaconazole. J Infect 54: 319–327.
59. Rinaldi M.G. (1996) Epidemiology of mycoses in the HIV infected patient: clinical aspects. Int J Antimicrob Agents 6: 131–134.
60. Saag M.S. Cloud G.A. Graybill J.R. Sobel J.D. Tuazon C.U. Johnson P.C. (1999) A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 28: 291–296.
61. Saag M.S. Graybill R.J. Larsen R.A. Pappas P.G. Perfect J.R. Powderly W.G. (2000) Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 30: 710–718.
62. Saag M.S. Powderly W.G. Cloud G.A. Robinson P. Grieco M.H. Sharkey P.K. (1992) Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 326: 83–89.
63. Salerno C.T. Ouyang D.W. Pederson T.S. Larson D.M. Shake J.P. Johnson E.M. (1998) Surgical therapy for pulmonary aspergillosis in immunocompromised patients. Ann Thorac Surg 65: 1415–1419.
64. Saraceno J.L. Phelps D.T. Ferro T.J. Futerfas R. Schwartz D.B. (1997) Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 112: 541–548.
65. Sarosi G.A. Voth D.W. Dahl B.A. Doto I.L. Tosh F.E. (1971) Disseminated histoplasmosis: results of long-term follow-up. A center for disease control cooperative mycoses study. Ann Intern Med 75: 511–516.
66. Segal B.H. Walsh T.J. (2006) Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 173: 707–717.
67. Shelburne S.A. III Darcourt J. White A.C. Jr Greenberg S.B. Hamill R.J. Atmar R.L. (2005a) The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 40: 1049–1052.
68. Shelburne S.A. Visnegarwala F. Darcourt J. Graviss E.A. Giordano T.P. White A.C. Jr (2005b) Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. Aids 19: 399–406.
69. Sheu S.J. Chen Y.C. Kuo N.W. Wang J.H. Chen C.J. (1998) Endogenous cryptococcal endophthalmitis. Ophthalmology 105: 377–381.
70. Silveira F.P. Husain S. (2007) Fungal infections in solid organ transplantation. Med Mycol 45: 305–320.
71. Silveira F.P. Husain S. Kwak E.J. Linden P.K. Marcos A. Shapiro R. (2007) Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transpl Infect Dis 9: 22–27.
72. Singh N. Dromer F. Perfect J.R. Lortholary O. (2008) Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 47: 1321–1327.
73. Singh N. Husain S. (2009) Invasive aspergillosis in solid organ transplant recipients. Am J Transplant 9(Suppl. 4): S180's191.
74. Singh N. Lortholary O. Alexander B.D. Gupta K.L. John G.T. Pursell K. (2005) An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 40: 1756–1761.
75. Sinko J. Csomor J. Nikolova R. Lueff S. Krivan G. Remenyi P. (2008) Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey. Transpl Infect Dis 10: 106–109.
76. Smith C.E. Beard R.R. (1946) Varieties of coccidioidal infection in relation to the epidemiology and control of the diseases. Am J Public Health Nations Health 36: 1394–1402.
77. Soubani A.O. Chandrasekar P.H. (2002) The clinical spectrum of pulmonary aspergillosis. Chest 121: 1988–1999.
78. Stevens D.A. Kan V.L. Judson M.A. Morrison V.A. Dummer S. Denning D.W. (2000) Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 30: 696–709.
79. Ullmann A.J. Lipton J.H. Vesole D.H. Chandrasekar P. Langston A. Tarantolo S.R. (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356: 335–347.
80. Vail G.M. Young R.S. Wheat L.J. Filo R.S. Cornetta K. Goldman M. (2002) Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis 4: 148–151.
81. van der Horst C.M. Saag M.S. Cloud G.A. Hamill R.J. Graybill J.R. Sobel J.D. (1997) Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 337: 15–21.
82. Vikram H.R. Blair J.E. (2009) Coccidioidomycosis in transplant recipients: a primer for clinicians in nonendemic areas. Curr Opin Organ Transplant 14: 606–612.
83. Vilchez R.A. Irish W. Lacomis J. Costello P. Fung J. Kusne S. (2001) The clinical epidemiology of pulmonary cryptococcosis in non-AIDS patients at a tertiary care medical center. Medicine (Baltimore) 80: 308–312.
84. Visnegarwala F. Graviss E.A. Lacke C.E. Dural A.T. Johnson P.C. Atmar R.L. (1998) Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors. Clin Infect Dis 27: 1231–1237.
85. Walsh T.J. Anaissie E.J. Denning D.W. Herbrecht R. Kontoyiannis D.P. Marr K.A. (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46: 327–360.
86. Walsh T.J. Finberg R.W. Arndt C. Hiemenz J. Schwartz C. Bodensteiner D. (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340: 764–771.
87. Wheat J. (1995) Endemic mycoses in AIDS: a clinical review. Clin Microbiol Rev 8: 146–159.
88. Wheat J. Hafner R. Korzun A.H. Limjoco M.T. Spencer P. Larsen R.A. (1995) Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med 98: 336–342.
89. Wheat L.J. Freifeld A.G. Kleiman M.B. Baddley J.W. McKinsey D.S. Loyd J.E. (2007) Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 45: 807–825.
90. White M. Cirrincione C. Blevins A. Armstrong D. (1992) Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis 165: 960–963.
91. White M.H. Bowden R.A. Sandler E.S. Graham M.L. Noskin G.A. Wingard J.R. (1998) Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27: 296–302.
92. Wilson M.L. Sewell L.D. Mowad C.M. (2008) Primary cutaneous Cryptococcosis during therapy with methotrexate and adalimumab. J Drugs Dermatol 7: 53–54.
93. Zinck S.E. Leung A.N. Frost M. Berry G.J. Muller N.L. (2002) Pulmonary cryptococcosis: CT and pathologic findings. J Comput Assist Tomogr 26: 330–334.